Class / Patent application number | Description | Number of patent applications / Date published |
514160600 | Rheumatoid arthritis affecting | 46 |
20100292152 | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases - Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases. | 11-18-2010 |
20100292153 | USE OF MURAMYL DIPEPTIDE (MDP) FOR TREATING INFLAMMATION - The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP). | 11-18-2010 |
20100298227 | Treatment of autoimmune conditions with Copolymer 1 and related copolymers - The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal. | 11-25-2010 |
20100305039 | Production of collagen in the milk of transgenic mammals - The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided. | 12-02-2010 |
20100323967 | RNA Antagonist Compounds for the Modulation of MCL-1 - Oligonucleotides directed against the Mcl-1 gene are developed for modulating the expression of Mcl-1 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Mcl-1. Methods of using these compounds for modulation of Mcl-1 expression and for the treatment of diseases associated with over expression of Mcl-1 are provided. Examples of such diseases include cancer and systemic mastocytosis. | 12-23-2010 |
20110028399 | CITRULLINATED CYTOKINES - The present invention provides natural occurring, recombinant and synthetic chemokines, interleukins and cytokines in which at least one arginine residue is replaced by or modified into a cltrulline residue. The present Invention also relates to the use of said chemokines, interleukins or cytokines and pharmaceutical compositions comprising said chemokines, interleukins or cytokines as anti-inflammatory agents and as haematopoietic cell (including stem-cell, progenitor cell and leukocyte) or endothelial cell mobilizing agents. Furthermore, the present invention relates to the use of said chemokines, interleukins or cytokines to create antibodies and to use said chemokines, interleukins, cytokines and/or said antibodies as diagnostic tools and as a medicine. In addition, the present invention provides for the processes for the identification and production of the citrullinated chemokines, interleukins or cytokines of the invention. | 02-03-2011 |
20110105401 | PEPTIDE COMPOSITION AND A METHOD OF PROMOTING CARTILAGE FORMATION - The present invention is a peptide compound which stimulates the formation of hard tissues such as bone and cartilage. The invention is also related to a method to treat a defect in hard tissues such as bone and cartilage using the peptide. The method of the present invention may be used to treat or prevent the defects in bones and cartilages which are caused by rheumatoid arthritis or osteoarthritis which involves the regeneration of new bone or cartilage in or around the defects. | 05-05-2011 |
20110124569 | MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT - The instant invention describes macrocyclic depsipeptide lyngbyastatins, and methods of treating disorders such as COPD, emphysema, rheumatoid arthritis, and aging related disorders. | 05-26-2011 |
20110136741 | DICARBA-ANALOGUES OF OCTREOTIDE - Analogues of octreotide, their preparation and use are described. | 06-09-2011 |
20110160136 | POLYPHENOLS FOR THE TREATMENT OF CARTILAGE DISORDERS - Compositions and methods for maintenance of cartilage health or prevention, alleviation and/or treatment of cartilage disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting cartilage growth or for the maintenance of cartilage health and methods regarding same. In an embodiment, the present invention provides a composition comprising an active ingredient having an effective amount of a plant or plant extract containing at least one phytochemical, in particular polyphenol having the ability to treat or prevent muscular skeletal diseases. | 06-30-2011 |
20110190211 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA - A cyclopenta[g]quinazoline derivative, containing an L-Glu-γ-D-Glu dipeptide group, of formula (I): wherein R | 08-04-2011 |
20110195905 | APLS FOR TREATING ARTHRITIS - One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient. | 08-11-2011 |
20110230413 | PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY IN MULTIPLE SCLEROSIS - A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10/IL-18 ratio and IL-10/IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo-/non-responder. | 09-22-2011 |
20110251129 | RHEUMATOID ARTHRITIS-PREVENTIVE AGENT FOR ORAL INTAKE - There is provided a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on rheumatoid arthritis and is excellent in safety. The rheumatoid arthritis inhibitor for oral intake of the present invention contains, as an active component, a casein hydrolysate containing free amino acids and peptides obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, or a mixture of free amino acids and peptides contained in the hydrolysate. | 10-13-2011 |
20110269686 | CXCR4 ANTAGONIST AND USE THEREOF - The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt. | 11-03-2011 |
20110306554 | PEPTIDE CAPABLE OF BINDING TO IMMUNOGLOBULIN - The present invention provides a peptide capable of binding to an immunoglobulin, a fusion protein with the peptide, nucleic acids coding for the peptide and for the fusion protein, methods for producing the peptide and the fusion protein, and a composition and means for binding an immunoglobulin, as well as a pharmaceutical composition for the treatment or prevention of a disease caused by the binding between C1q and an immunoglobulin, which includes a peptide capable of binding to the immunoglobulin or a fusion protein with the peptide, and others. | 12-15-2011 |
20120028903 | MODULATION OF THE ACTIVITY AND DIFFERENTIATION OF CELLS EXPRESSING THE OSTEOCLAST-ASSOCIATED RECEPTOR - This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells. | 02-02-2012 |
20120065140 | Biomarkers for the Diagnosis of Autoimmune Disease - Compositions and methods are provided for diagnosis and treatment of rheumatoid arthritis. Defects in T cell receptor signaling lower the activation threshold of RA T cells, thus predisposing for a failure in maintenance of immune tolerance. Overexpression of B-Raf and/or K-Ras in CD4 T cells lowers the threshold to respond to TCR triggering in the absence of costimulation and increases responses to citrullinated peptides and other autoantigens. | 03-15-2012 |
20120094914 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS OR RHEUMATOID ARTHRITIS-RELATED DISEASES - Disclosed is a prophylactic or therapeutic agent for rheumatoid arthritis or diseases caused by rheumatoid arthritis (rheumatoid arthritis-related diseases), which comprises HLA-G or a dimer thereof as an active ingredient. As the HLA-G, the following protein (a) or (b) are suitably used.
| 04-19-2012 |
20120129779 | TUBULYSINE DERIVATIVES - The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases. | 05-24-2012 |
20120225820 | PEPTIDES ASSOCIATED WITH HLA-DR MHC CLASS II MOLECULE AND INVOLVED IN RHEUMATOID ARTHRITIS - Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with rheumatoid arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of rheumatoid arthritis. | 09-06-2012 |
20120245091 | POLYPEPTIDE OR FUSED PROTEIN THEREOF INHIBITING THE EXTRAVASATION OF WHITE BLOOD CELLS OR THE GROWTH AND/OR METASTASIS OF CANCER CELLS - The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer. | 09-27-2012 |
20120309686 | Treatment of Rheumatoid Arthritis With Mammal Beta Defensins - The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins. | 12-06-2012 |
20130012445 | Compositions for Improving Bone Mass - The present invention provides a therapeutic composition, and method of use thereof, for improving bone mass, rigidity, or strength, or preventing and treating bone loss via modulation of the RANK signaling pathway. The therapeutic composition of the present invention comprises a RYBP peptide, or fragments thereof, that specifically interact with a motif of RANK to regulate osteoclastogenesis. The present invention further provides a composition, and method of use thereof, comprising a modulator that is capable of modulating the RYBP-RANK interaction, or modulating an effector in the RANK signaling pathway through the RYBP-RANK interaction. | 01-10-2013 |
20130017998 | NOVEL MODIFIED GALECTIN 9 PROTEINS AND USE THEREOF - A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response. | 01-17-2013 |
20130079284 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 03-28-2013 |
20130130987 | METHODS FOR INHIBITING IMMUNE COMPLEX FORMATION IN A SUBJECT - Polypeptides and other compounds that can bind specifically to the C | 05-23-2013 |
20130130988 | MACROMOLECULAR COMPLEX OF BACTERIAL ORIGIN AND USE OF SAID MACROMOLECULAR COMPLEX FOR PREVENTING AND TREATING INFLAMMATORY RHEUMATISM - A bacterial macromolecular complex produced by bacteria belonging to the | 05-23-2013 |
20130237484 | HUMAN-DERIVED CELL-PERMEABLE PEPTIDE BIOACTIVE PEPTIDE CONJUGATE, AND USE THEREOF - The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. | 09-12-2013 |
20140018298 | CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA - The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment. | 01-16-2014 |
20140094412 | SELECTIVE ALFAVBETA3 RECEPTOR PEPTIDE ANTAGONIST FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The present invention is related to new peptide antagonists of α | 04-03-2014 |
20140107034 | SOLUBLE HYBRID FCGAMMA RECEPTORS AND RELATED METHODS - Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides. | 04-17-2014 |
20140113867 | APLS FOR TREATING ARTHRITIS - One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient. | 04-24-2014 |
20140235544 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDES OR THEIR INHIBITORS - The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease. | 08-21-2014 |
20140243273 | METHODS FOR TREATING INFLAMMATORY DISEASES AND PHARMACEUTICAL COMBINATIONS USEFUL THEREFOR - The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of Formula I and an optional co-therapy (e.g., chemotherapy agent, DMARD, or any combination thereof). The present invention also provides a pharmaceutical composition comprising a compound of Formula I, a method of manufacturing a pharmaceutical composition comprising a compound of Formula I, and a method of administering a pharmaceutical composition comprising a solid form of a compound of Formula I. | 08-28-2014 |
20140371150 | PEPTIDES TARGETING RECEPTOR ACTIVATOR OF NUCLEAR FACTOR - KAPPA B (RANK) AND THEIR APPLICATIONS - The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease. | 12-18-2014 |
20140378384 | POLYPEPTIDES IN PREPARATION OF DRUGS FOR TREATMENT OR PREVENTION OF RHEUMATOID ARTHRITIS - A series of polypeptides presenting high integrin affinity and bonding capacity is provided. Three polypeptides among said series can be adopted in prevention and treatment of rheumatoid arthritis. Said three polypeptides are: polypeptide I: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro (SEQ ID NO. 1) (two pairs of disulfide bonds contained in the sequence are pairing in the pattern of 1-4 and 2-3); Polypeptide II: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO. 2); and polypeptide III: mPEG-SC | 12-25-2014 |
20160024183 | SYNTHETIC PEPTIDES FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder. | 01-28-2016 |
20160031957 | INHIBITORS OF THE LINEAR UBIQUITIN CHAIN ASSEMBLY COMPLEX (LUBAC) AND RELATED METHODS - The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphboma (ABC DLBCL) and autoimmune or inflammatory disorders. | 02-04-2016 |
20160058836 | IK FACTOR AND PHARMACEUTICAL USE OF NUCLEIC ACID ENCODING IK FACTOR - The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis. | 03-03-2016 |
20160095895 | HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORS - The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble FcγRIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved. | 04-07-2016 |
20160130323 | NOVEL PEPTIDES THAT BIND TO TYPES OF MHC CLASS II AND THEIR USE ON DIAGNOSIS AND TREATMENT - It is provided novel peptides from human alpha-enolase, collagen type II and vimentin that bind to types of MHC class II that is associated with rheumatoid arthritis. There is also provided novel therapies and methods for diagnosis of rheumatoid arthritis. | 05-12-2016 |
20160137691 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE - The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in combination with another drug. The present invention relates to: an α-oxoacyl aminocaprolactam derivative that is represented by formula (I) | 05-19-2016 |
20160166636 | MODIFIED PEPTIDES AND THEIR USE FOR TREATING CHRONIC INFLAMMATORY DISEASES | 06-16-2016 |
20160176934 | Ang-2 Binding Complexes and Uses Thereof | 06-23-2016 |
20170232061 | Soluble Mediator | 08-17-2017 |